ZURICH (Reuters) – A European Medicines Agency (EMA) panel recommended on Friday approval of a new Novartis drug to be used against a tough-to-cure form of blood cancer as the Swiss drugmaker makes headway on refreshing its oncology portfolio. The EMA’s Committee for Medicinal Products for Human Use (CHMP) backed Rydapt against acute myeloid leukemia […]
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
A breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely following a discount deal between Roche and the NHS.
Roche’s seven-year-old rheumatoid arthritis drug Actemra is being linked to hundreds of deaths due to undisclosed side effects.
While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?
Roche is investigating a case of a German patient diagnosed with a deadly brain infection called PML after taking one dose of the company’s new MS drug Ocrevus.
The world needs greater transparency on the pricing of medicines – and an overhaul of some approaches – in order to increase access to life-saving drugs, global health experts said.
Life expectancy for young HIV-positive adults has risen by 10 years in the United States and Europe.
Spending on prescription medicines in the United States will increase 4-7 percent through 2021, reaching $580 billion to $610 billion, according to a report released by QuintilesIMS Holdings.
Teva Pharmaceutical Industries Ltd. launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
President Trump, hoping to take on the opioid epidemic sweeping parts of America, tapped U.S. Rep. Tom Marino to head up the Office of National Drug Control Policy.
As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.
GlaxoSmithKline’s new CEO Emma Walmsley won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
Two U.S. lawmakers sent a letter to PTC Therapeutics Inc. seeking information about the drugmaker’s pricing strategy for its recently acquired muscle-wasting disorder drug.
Nearly all patients who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni were cured of the disease, according to PBM Prime Therapeutics.
Congressional Republicans recrafted their Obamacare replacement bill in hopes of satisfying critics.
CytomX Therapeutics and Bristol-Myers Squibb are strengthening their relationship with the expansion of a 2014 collaboration agreement. The companies announced a plan to include up to eight additional targets, six in oncology and two in non-oncology areas, using CytomX’s proprietary Probody platform.
President Donald Trump backed a draft U.S. House of Reps’ Republican bill to repeal and replace the Obamacare healthcare law that is open to negotiation.
Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
As a public official preparing for international negotiations, I was taught by the U.S. State Department to always know exactly what you want and what you’re willing to give up before sitting down with a skilled international trading partner. It looks like pharma representatives were well prepared recently when sitting down with the country’s new Negotiator-in-Chief, President Donald Trump, but they should be mindful that the other shoe has yet to drop.